Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.73 |
| ▸ | CDK1 | P06493 | 8/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552760 | 1.00 | CDK2 (0.73) | CDK2KCNH2CDK1CDK4CCNB1 | |
| SCHEMBL3549414 | 0.93 | CDK2 (0.75) | CDK2KCNH2CDK1 | |
| SCHEMBL17530717 | 0.89 | CDK2 (0.72) | CDK2KCNH2CDK1 | |
| SCHEMBL3557539 | 0.85 | CDK2 (0.77) | CDK2KCNH2CDK1 | |
| SCHEMBL3544541 | 0.85 | CDK2 (0.88) | CDK2KCNH2CDK1 | |
| SCHEMBL3552191 | 0.85 | CDK2 (0.88) | CDK2KCNH2CDK1 | |
| SCHEMBL3548395 | 0.84 | CDK2 (1.00) | CDK2KCNH2CDK1 | |
| SCHEMBL3548509 | 0.84 | CDK2 (0.75) | CDK2KCNH2CDK1 | |
| SCHEMBL3557201 | 0.83 | CDK2 (0.74) | CDK2KCNH2CDK1 | |
| SCHEMBL3547141 | 0.83 | CDK2 (0.74) | CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | CDK2 84/4885KCNH2 4616/4885CDK1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.